What is ACN's intrinsic value?

TickerWorth's valuation lenses put Accenture plc (ACN) between $85.60 and $366.42 per share, versus a market price of $229.68. They disagree too widely for us to state a single fair value, so we publish the range.

Is ACN overvalued or undervalued?

At $229.68 the price sits inside a range too wide to call either way. We don't call ACN overvalued or undervalued from a range this wide. This is an educational estimate, not advice.

What discount rate is used for ACN?

A WACC of 10.2% and a terminal growth rate of 2.5%.

Is Accenture stock undervalued?

TickerWorth's fair-value range for Accenture plc (ACN) is $85.60 – $366.42 against a market price of $229.68. Too wide to call. We publish a range here, not one number, so we do not call it over- or undervalued. This is a model estimate, not investment advice.

Accenture (ACN) DCF valuation and fair value

Our fair-value range for Accenture plc (ACN) is $85.60 – $366.42, built on a 10.2% discount rate (WACC) and 2.5% terminal growth. It blends our discounted-cash-flow model with other valuation lenses. Every assumption is listed on this page with its source.

What growth is priced into Accenture stock?

Today's price implies revenue growth of 4.5% a year for 5 years; our model assumes 3.4% a year on average over the same horizon. This is a reverse DCF: it holds our cash-flow model's other inputs and solves for the revenue growth that makes the model equal today's price of $229.68. A model estimate, not investment advice.

Accenture (ACN) insider trading

The most recent insider filing (SEC Form 4) for Accenture plc (ACN): Hogan Catherine Kiernan, Chief Operating Officer, open-market sale on 2026-10-12. The latest filings are listed on this page. A disclosure, not a signal to trade.

ACN · Intrinsic value

Is Accenture plc (ACN) overvalued or undervalued?

Name: Accenture plc (ACN) DCF intrinsic value
Creator: TickerWorth

As of Oct 19, 2026, TickerWorth's valuation lenses put Accenture plc (ACN) at $85.60 – $366.42, too broad a range to say where the delayed market price of $229.68 sits in it, so we do not call it over- or undervalued. It is a model estimate, and every input behind it is sourced below.

Model by Miraaj Patel · generated from a hand-researched model · Updated Oct 19, 2026 · How these pages are made

Open full ACN analysis

What is ACN worth?

Fair-value range: $85.60 – $366.42
Market price: $229.68
Gap to fair value: —
Verdict: Too wide to call

Price as of 19 Oct 2026, 13:15 UTC · Prices are delayed.Our valuation lenses disagree too widely on this company for us to publish a single number, so we publish the range instead. We do not call it over- or undervalued from a spread this wide.

Fair-value range against the delayed market price: Too wide to call.

Reverse DCF: Today's price implies revenue growth of 4.5% a year for 5 years; our model assumes 3.4% a year on average over the same horizon.

What is ACN's TickerWorth Score?

C53/100

Middle of the pack — real strengths and real weaknesses

Compared with Technology companies in US

Its strongest point: looks cheap on the numbers. Its weakest: growth is slow or negative.

Value · 79 of 100
Cheaper than 79% of Technology companies in US
Price vs worth · 42 of 100
Quality · 50 of 100
More profitable than 50% of Technology companies in US
Financial health · 52 of 100
Financially stronger than 52% of Technology companies in US
Growth · 26 of 100
Growing faster than 26% of Technology companies in US
Momentum · 52 of 100
Outperformed 52% of Technology companies in US over the past year

Confidence: Medium confidence · Scored 19 Oct 2026, 13:15 UTC

Get the Undervalued Company of the Week.

Where the numbers come from

Hand-researched model

What the modeller flagged

THE MODEL AGREES WITH THE MARKET WITHIN A FEW PERCENT - AND THAT IS A CONCLUSION ABOUT INPUTS, NOT A TARGET. Nothing here was tuned toward the price. On house inputs (5.24% Treasury, 1.09 published beta, 5% ERP -> ~10.2% WACC) a ~16% operating margin on ~2.5-3% organic growth is worth roughly what Accenture trades at. The disagreement worth having is GenAI: the price looks like it already discounts low-single-digit organic growth, not a collapse - and also not a return to the 2021-22 boom.
TERMINAL VALUE IS ~70% OF ENTERPRISE VALUE - under the 75% line. The WACC +/-1.5pt and terminal growth +/-1pt grid runs ~$150-$280.
YEAR-1 FCF IS ~22% BELOW THE LAST REPORTED FCF ($8.5B modeled for FY2026 vs $10.9B reported for FY2025, and ~27% below FY2026's reported $11.6B) - past the 20% line, so explained. The gap is mostly stock compensation (~$2.1B a year, ~2.8% of revenue), which Accenture's FCF adds back and this model keeps as a cost; the rest is the cash-flow line's non-cash 'other' items (lease right-of-use amortization, which is matched by lease payments, and deferred transition-cost amortization) that the model does not add back. It is a definitional haircut, not a forecast that cash generation falls.
TIMING - THE MODEL IS A YEAR BEHIND THE CALENDAR AND THAT MAKES IT SLIGHTLY CONSERVATIVE. Year 1 (FY2026) already happened, yet it is discounted as if a year away, and its cash has already been paid out (and is therefore partly double-counted against the August-2026 balance sheet). Re-running the same economics with FY2026 as the base and FY2027-31 as the forecast gives ~$200 instead of the published figure: net, the year-behind convention costs ~$6/share. Re-base when the FY2026 10-K lands (~mid-October 2026).
THE ACQUISITION TREATMENT IS THE BIGGEST STRUCTURAL CHOICE. If Accenture overpays - Dragos, runZero and NetRise cost ~$4.2B in enterprise value for ~$208M of combined ARR (SecurityWeek, 2026-06-18) - the value-neutral assumption is generous; if its deals earn more than ~10%, it is stingy. Not modeled either way.
AMORTIZATION ADD-BACK OVERSTATES SLIGHTLY IN PERPETUITY: with no new deals, past-deal amortization would run off and EBIT would be taxed on it. The forgone tax shield is ~0.27% of revenue (25.5% x ~1.07%), worth up to ~$4-5/share - less if, as is common for share deals, the amortization is not tax-deductible in the first place. Disclosed rather than adjusted.
SBC of ~$2.1B (FY2026 $2,100M, FY2025 $2,094M) is expensed inside GAAP operating income and NOT added back; the dilution it causes is visible in the share count, which is nonetheless falling because buybacks ($7.5B in FY2026; at least $9.5B of total returns guided for FY2027) outrun it. Future buybacks are not credited as value.
GENAI IS THE CENTRAL JUDGEMENT AND THE MODEL IS LESS SENSITIVE TO IT THAN THE HEADLINES. Holding everything else, organic growth of 0% in FY2028-30 with margins stuck at 15.5% takes the value ~$9/share lower; 0% growth AND margin sliding to 14% takes it ~$23 lower; 5% organic growth adds ~$6. The bigger risk to this number is margin, not growth - a services firm forced to pass all AI productivity to clients while still paying severance to reshape its workforce.

Why ACN gets a range, not one number

At a recent price of $229.68, Accenture plc (ACN) sits inside a range too wide to call either way: our valuation lenses put the business somewhere between $85.60 and $366.42 per share. They disagree too widely for us to state a single fair value. We publish the range rather than a midpoint because a number that precise would claim more than the methods can support. This is an educational model, not a price target or a recommendation.

Read the full reasoning

The valuation discounts Accenture plc's projected free cash flows at a weighted-average cost of capital (WACC) of 10.2%, with a long-run terminal growth rate of 2.5%. About 70% of the enterprise value comes from the terminal value — the portion beyond the explicit forecast window — which is typical for a stable, cash-generative business and a reminder that small changes in the discount rate or terminal growth assumption swing the intrinsic value meaningfully.

Running the DCF in reverse — solving for the growth the current price already assumes — the market is implying roughly 4.5% annual revenue growth for ACN. Our base case instead compounds to about 3.4% a year over the same forecast, so the market's implied growth is broadly in line with our base case. The reverse-DCF is a quick sanity check: it reframes 'is this stock cheap?' as 'do I believe the growth the price requires?' rather than arguing over a single point estimate of fair value.

Sensitivity matters more than any single number. Across a reasonable band of discount-rate assumptions, ACN's modeled DCF value ranges from about $150.14 to $277.41 per share. If that range still sits below today's price, the market is optimistic relative to the model across the whole band; if it brackets the price, the stock is roughly fairly valued on our assumptions. Use the interactive slider to see exactly where your own cost-of-capital view lands.

How to read this page: the DCF fair value is what Accenture plc would be worth if its cash flows grow as modeled and are discounted at the stated WACC. The assumptions table shows every input and its source; the reverse-DCF shows what the market believes; the sensitivity band shows how fragile the answer is. None of this is investment advice — it is a transparent, auditable framework for forming your own view of ACN's intrinsic value. Figures update as new filings and prices come in.

Every input behind ACN's DCF

Input	Value	Source
Base-year revenueAccenture FY2025 10-K (accession 0001467373-25-000217, filed 2025-10-10): us-gaap:Revenues FY2025 = $69,672,977K, +7.4% on FY2024's $64,896M (+7% local currency). WHY FY2025 AND NOT FY2026: the FY2026 10-K is NOT yet filed (EDGAR submissions checked 2026-10-03; Accenture filed the FY2025 10-K on 2025-10-10, so FY2026's is due ~mid-October). The house rule is that the base year needs a filed 10-K, so FY2025 is the base and the already-completed FY2026 is Year 1 of the forecast, read off the unaudited Q4 release of 2026-10-01. CROSS-CHECK: FY2026 revenue was $74,183M, +6.5% in USD and +5% in local currency (release), of which the CFO said roughly 3 points were organic and the rest acquisitions; FX added ~2 points.	$69,672,977,000	Accenture FY2025 10-K (accession 0001467373-25-000217, filed 2025-10-10): us-gaap:Revenues FY2025 = $69,672,977K, +7.4% on FY2024's $64,896M (+7% local currency). WHY FY2025 AND NOT FY2026: the FY2026 10-K is NOT yet filed (EDGAR submissions checked 2026-10-03; Accenture filed the FY2025 10-K on 2025-10-10, so FY2026's is due ~mid-October). The house rule is that the base year needs a filed 10-K, so FY2025 is the base and the already-completed FY2026 is Year 1 of the forecast, read off the unaudited Q4 release of 2026-10-01. CROSS-CHECK: FY2026 revenue was $74,183M, +6.5% in USD and +5% in local currency (release), of which the CFO said roughly 3 points were organic and the rest acquisitions; FX added ~2 points.
Base EBIT marginAccenture FY2025 10-K (accession 0001467373-25-000217, filed 2025-10-10): GAAP operating income $10,225.7M / revenue $69,673.0M = 14.68%. Accenture reports an operating-income line, so nothing is derived. It is AFTER $615.3M of 'business optimization costs' ($344M severance + $271M impairments on two divested acquisitions); Accenture's adjusted margin excluding them was 15.6%. I use the GAAP figure because those costs RECUR: FY2023 $1,063M, FY2024 $438M, FY2025 $615M, FY2026 $308M - four fiscal years running, ~0.9% of revenue on average (FY2024-26 ex the non-cash impairment ~0.5%). See forecast.ebit_margin for how that becomes an allowance. CROSS-CHECK FY2026 (release): GAAP $11,406.0M / $74,183.4M = 15.38% (adjusted 15.8%); Q4 FY2026 alone 15.3% with no optimization charge.	14.7%	Accenture FY2025 10-K (accession 0001467373-25-000217, filed 2025-10-10): GAAP operating income $10,225.7M / revenue $69,673.0M = 14.68%. Accenture reports an operating-income line, so nothing is derived. It is AFTER $615.3M of 'business optimization costs' ($344M severance + $271M impairments on two divested acquisitions); Accenture's adjusted margin excluding them was 15.6%. I use the GAAP figure because those costs RECUR: FY2023 $1,063M, FY2024 $438M, FY2025 $615M, FY2026 $308M - four fiscal years running, ~0.9% of revenue on average (FY2024-26 ex the non-cash impairment ~0.5%). See forecast.ebit_margin for how that becomes an allowance. CROSS-CHECK FY2026 (release): GAAP $11,406.0M / $74,183.4M = 15.38% (adjusted 15.8%); Q4 FY2026 alone 15.3% with no optimization charge.
Forecast revenue growthESTIMATEAssumption — TickerWorth's 5-year explicit forecast	6% → 2% → 2% → 3% → 3%	ESTIMATEAssumption — TickerWorth's 5-year explicit forecast
Risk-free rateUS 10Y Treasury constant maturity (FRED DGS10): 5.24% on 2026-10-01, the latest published observation. Shared by every model in this tracker.	5.2%	US 10Y Treasury constant maturity (FRED DGS10): 5.24% on 2026-10-01, the latest published observation. Shared by every model in this tracker.
BetaYahoo Finance 5Y-monthly beta via yfinance, read 2026-10-03: Published 5Y-monthly beta 1.092, used AS IS (rounded to 1.09) - no normalization. Accenture's beta has historically sat around 1.0-1.2, so the figure is not an outlier. Caveat in both directions: the June-July 2026 collapse (a record one-day fall of ~18-20% on 2026-06-18, a low near $118) and the October rebound are only a handful of the ~60 monthly observations, so the regression barely registers the new GenAI-driven volatility, which argues for a HIGHER beta; but a services firm with ~9,000 clients and multi-year managed-services contracts is less cyclical than the market, which argues for lower. Held at published. Each 0.1 of beta is worth roughly $11-12/share; the reverse DCF says a beta of ~1.04 closes the gap.	1.09	Yahoo Finance 5Y-monthly beta via yfinance, read 2026-10-03: Published 5Y-monthly beta 1.092, used AS IS (rounded to 1.09) - no normalization. Accenture's beta has historically sat around 1.0-1.2, so the figure is not an outlier. Caveat in both directions: the June-July 2026 collapse (a record one-day fall of ~18-20% on 2026-06-18, a low near $118) and the October rebound are only a handful of the ~60 monthly observations, so the regression barely registers the new GenAI-driven volatility, which argues for a HIGHER beta; but a services firm with ~9,000 clients and multi-year managed-services contracts is less cyclical than the market, which argues for lower. Held at published. Each 0.1 of beta is worth roughly $11-12/share; the reverse DCF says a beta of ~1.04 closes the gap.
Terminal growthESTIMATEAssumption — house default: House default 2.5% (roughly long-run nominal GDP), kept for comparability. It is ORGANIC growth forever, consistent with the forecast excluding acquisitions. Not generous for a firm that grew organically ~3% even in a weak FY2026, but not conservative if GenAI permanently shrinks the billable-hours pool - which is exactly the debate. 2.0% takes ~$9/share off; 3.0% adds ~$10. Must stay well below the ~10.2% WACC; it does.	2.5%	ESTIMATEAssumption — house default: House default 2.5% (roughly long-run nominal GDP), kept for comparability. It is ORGANIC growth forever, consistent with the forecast excluding acquisitions. Not generous for a firm that grew organically ~3% even in a weak FY2026, but not conservative if GenAI permanently shrinks the billable-hours pool - which is exactly the debate. 2.0% takes ~$9/share off; 3.0% adds ~$10. Must stay well below the ~10.2% WACC; it does.
Diluted sharesAccenture Q4/FY2026 earnings release, 8-K Ex-99.1 (accession 0001467373-26-000037, filed 2026-10-01): Q4 FY2026 weighted-average diluted shares 605,283,767 - the latest quarter (full-year FY2026 617.5M; FY2025 632.4M). The count includes Accenture Canada Holdings exchangeable shares (treated as converted one-for-one), so that small noncontrolling interest is NOT also subtracted in net debt. ~596M shares were outstanding at 2026-08-31 after 39.9M were repurchased or redeemed in FY2026 ($7.5B); the count is FALLING ~2-3% a year because buybacks outrun ~$2.1B a year of stock compensation.	605M	Accenture Q4/FY2026 earnings release, 8-K Ex-99.1 (accession 0001467373-26-000037, filed 2026-10-01): Q4 FY2026 weighted-average diluted shares 605,283,767 - the latest quarter (full-year FY2026 617.5M; FY2025 632.4M). The count includes Accenture Canada Holdings exchangeable shares (treated as converted one-for-one), so that small noncontrolling interest is NOT also subtracted in net debt. ~596M shares were outstanding at 2026-08-31 after 39.9M were repurchased or redeemed in FY2026 ($7.5B); the count is FALLING ~2-3% a year because buybacks outrun ~$2.1B a year of stock compensation.
Market priceDelayed quote · as of 2026-10-19 13:15 UTC	$229.68	Delayed quote · as of 2026-10-19 13:15 UTC

Change ACN's assumptions

The discount-rate dial and the editable model

Pro

Change growth, margin and WACC yourself — Pro (7-day free trial, card required).

Start free trial Try it on Apple

What does Accenture plc do?

What does it do?

Accenture plc provides consulting and managed services in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It offers artificial intelligence and data; cloud consulting; cybersecurity consulting; digital engineering and manufacturing; ecosystem partners; emerging technology; finance and risk management consulting; infrastructure and capital projects; digital learning; supply chain consulting; technology consulting; sustainability consulting; and metaverse solutions, as well as customer services. It operates in the Information Technology Services industry (Technology sector), headquartered in Ireland. The company employs roughly 814,000 people.

How does it make money?

The business turns $74.2B in annual revenue into profit. Out of every $100 of sales, about $18 is left as operating profit (operating margin of 17.8%), after a 32% gross margin on the products/services it sells. After all costs, taxes and interest, 11.3% of revenue becomes bottom-line net profit.

Is it financially healthy?

Financially it looks mixed: carries modest debt (0.4× equity), can just cover its short-term bills (1.4× current ratio), and is currently profitable.

Who at ACN filed insider trades?

Recent insider filings for Accenture plc
Date	Insider	Relationship	What happened	Value	Filing
12 Oct 2026	Hogan Catherine Kiernan	Chief Operating Officer	Open-market sale	$210.80	Form 4 for Hogan Catherine Kiernan (opens sec.gov in a new tab)
12 Oct 2026	Hogan Catherine Kiernan	Chief Operating Officer	Open-market sale	$46,691.94	Form 4 for Hogan Catherine Kiernan (opens sec.gov in a new tab)
12 Oct 2026	Hogan Catherine Kiernan	Chief Operating Officer	Open-market sale	$51,822.39	Form 4 for Hogan Catherine Kiernan (opens sec.gov in a new tab)
12 Oct 2026	Hogan Catherine Kiernan	Chief Operating Officer	Open-market sale	$44,316.70	Form 4 for Hogan Catherine Kiernan (opens sec.gov in a new tab)
12 Oct 2026	Hogan Catherine Kiernan	Chief Operating Officer	Open-market sale	$6,923.52	Form 4 for Hogan Catherine Kiernan (opens sec.gov in a new tab)
8 Oct 2026	Hogan Catherine Kiernan	Chief Operating Officer	Open-market sale	$264,000.00	Form 4 for Hogan Catherine Kiernan (opens sec.gov in a new tab)

A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans

Common questions

What is ACN's intrinsic value?
TickerWorth's valuation lenses put Accenture plc (ACN) between $85.60 and $366.42 per share, versus a market price of $229.68. They disagree too widely for us to state a single fair value, so we publish the range.
Is ACN overvalued or undervalued?
At $229.68 the price sits inside a range too wide to call either way. We don't call ACN overvalued or undervalued from a range this wide. This is an educational estimate, not advice.
What discount rate is used for ACN?
A WACC of 10.2% and a terminal growth rate of 2.5%.
Is Accenture stock undervalued?
TickerWorth's fair-value range for Accenture plc (ACN) is $85.60 – $366.42 against a market price of $229.68. Too wide to call. We publish a range here, not one number, so we do not call it over- or undervalued. This is a model estimate, not investment advice.
Accenture (ACN) DCF valuation and fair value
Our fair-value range for Accenture plc (ACN) is $85.60 – $366.42, built on a 10.2% discount rate (WACC) and 2.5% terminal growth. It blends our discounted-cash-flow model with other valuation lenses. Every assumption is listed on this page with its source.
What growth is priced into Accenture stock?
Today's price implies revenue growth of 4.5% a year for 5 years; our model assumes 3.4% a year on average over the same horizon. This is a reverse DCF: it holds our cash-flow model's other inputs and solves for the revenue growth that makes the model equal today's price of $229.68. A model estimate, not investment advice.
Accenture (ACN) insider trading
The most recent insider filing (SEC Form 4) for Accenture plc (ACN): Hogan Catherine Kiernan, Chief Operating Officer, open-market sale on 2026-10-12. The latest filings are listed on this page. A disclosure, not a signal to trade.